AMO to be acquired by Abbott

Article

Advanced Medical Optics (AMO) has been acquired by Abbott, a global pharmaceutical and medical device company, the companies have announced in a statement.

Advanced Medical Optics (AMO) is to be acquired by Abbott, a global pharmaceutical and medical device company, the companies have announced in a statement. The $2.8 billion acquisition is expected by both companies to be completed in the first quarter of this year.

Abbott, one of the world's largest healthcare companies, currently has no presence in the ophthalmic market, although it markets its products in 130 countries globally. The acquisition will allow Abbott to take advantage of AMO's leading position in the LASIK surgical devices market, and to capitalize on the company's top-three position in the cataract surgical devices and contact lens care products markets.

Abbott will acquire AMO at $22 per share in a cash transaction, commencing on January 26, 2009. Jim Mazzo, the current chairman and chief executive officer of AMO will remain as AMO's president when the acquisition is complete.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.